Lurasidone (Latuda): Uses, Dosing, Side Effects & Safety

What It's Used For

Latuda (lurasidone) is used to treat schizophrenia and bipolar depression (depressive episodes in bipolar I disorder). In psychiatry, it’s a go-to when you want antipsychotic benefits with a generally more weight-friendly profile than many alternatives—while still respecting the trade-offs like akathisia, parkinsonism, and rare but serious reactions.

Primary Indications

Schizophrenia: Helps reduce hallucinations, delusions, disorganization, and agitation over timeBipolar I depression: Treats the depressive phase (not acute mania/hypomania)Adjunct option (adults): Can be combined with lithium or divalproex for bipolar depression

Off-Label Uses

Bipolar depressive episodes with mixed featuresMajor depressive disorder with mixed featuresPostpartum psychosis (specialist-directed)

How Fast It Works

Latuda isn’t an instant tranquilizer. It’s more of a steady-build medication—early changes first, then deeper improvement over weeks.

Within 1 week (often)

early improvement in bipolar depression can start showing up

1–2 weeks

early schizophrenia symptom shifts may begin (less intensity, less agitation)

4–6 weeks

fuller effect is more likely to be noticeable and consistent

Once daily dosing

long half-life supports daily dosing rather than multiple times per day

Food is part of the dose

taking it with ≥350 calories meaningfully changes how much medication your body absorbs

Safe Discontinuation

With chronic psychiatric illness, switching is often safer than “just stopping,” especially if Latuda is controlling psychosis or bipolar depression. If stopping is the plan, taper gradually over weeks to months so you can catch early relapse signals and reduce withdrawal reactions (agitation, anxiety, insomnia, sweating, GI upset, tremor, dyskinesias). If discontinuation is due to a serious adverse effect, the plan may need to be faster—this is where specialist guidance matters.

Key Points

Don’t stop abruptly unless there’s a serious adverse effect requiring urgent discontinuation.
Taper over several weeks to months when possible to reduce withdrawal symptoms and detect symptom recurrence early.
Withdrawal symptoms can include agitation, anxiety, insomnia, sweating, GI symptoms, chills/warmth waves, tremor, restlessness, dizziness/vertigo, dyskinesias, and return of psychosis or mood symptoms.
If switching antipsychotics: common strategies include cross-titration, overlap-and-taper, or (less commonly) abrupt change with careful monitoring; relapse risk level should drive how conservative you are.
If schizophrenia relapse risk is high, clinicians may overlap (keep the current med stable while the new med reaches a therapeutic dose) before tapering the first medication.

Dosing Information

Adult Dosing

schizophrenia initial: 40 mg PO once daily in the evening within 30 minutes of food (≥350 calories); consider 20 mg once daily for first-episode psychosis or sensitivity to side effects

schizophrenia titration: Increase in 40 mg increments no sooner than every 3 days based on response and tolerability; monitor akathisia, parkinsonism, and sedation during titration

schizophrenia typical: 40 to 80 mg/day; use the lowest effective maintenance dose

schizophrenia max: 160 mg/day

bipolar depression initial: 20 mg PO once daily in the evening within 30 minutes of food (≥350 calories)

bipolar depression titration: Increase by 20 mg increments every ≥2 days based on response and tolerability

bipolar depression max: 120 mg/day

mdd mixed features initial: 20 mg PO once daily in the evening within 30 minutes of food (≥350 calories) for 7 days

mdd mixed features titration: After day 7, increase by 20 mg every 2 to 7 days based on response and tolerability

mdd mixed features max: 60 mg/day

postpartum psychosis initial: 40 mg PO once daily in the evening within 30 minutes of food (≥350 calories)

postpartum psychosis titration: After 3 days increase to 80 mg once daily; after 2 to 3 additional days may increase further up to 160 mg/day over ~1 week based on response and tolerability

postpartum psychosis duration: Continue treatment for 3 to 6 months (specialist-guided)

renal impairment: CrCl <50 mL/min: Start 20 mg PO daily; maximum 80 mg/day (CrCl ≥50 mL/min: no adjustment)

hepatic impairment: Child-Pugh B: Start 20 mg PO daily; maximum 80 mg/day. Child-Pugh C: Start 20 mg PO daily; maximum 40 mg/day (Child-Pugh A: no adjustment)

older adults: Use lower-end adult doses and titrate slowly; avoid for dementia-related behavioral symptoms unless nonpharmacologic strategies fail and there is risk of harm; monitor falls, orthostasis, sodium, and movement symptoms closely

Simple Explanation

Latuda is usually once daily. The single most important dosing rule is food: take it with at least 350 calories or you won’t absorb enough. Dose increases should be slow enough to catch akathisia, stiffness, sedation, or blood pressure drops early. Kidney and liver impairment lower your safe maximum dose.

Available Formulations

Tablets: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg (brand and generic availability varies by country)
Administration: Once daily with food (≥350 calories), ideally at the same time each day

Critical Safety Information

Not approved for dementia-related psychosis. Antipsychotics raise the risk of death in older adults with dementia-related psychosis.

→Take Latuda with at least 350 calories every time. If you skip the food, you may be under-dosing without realizing it.
→Call urgently for high fever + muscle stiffness + confusion (possible NMS).
→Report restlessness you can’t control (akathisia), new tremor/stiffness, or swallowing problems—these can be movement side effects that need fast fixes.
→Stand up slowly and hydrate, especially early on—dizziness and fainting can happen.
→If you’re older or medically fragile, fall risk is real. Build in safety (night lights, slow position changes).
→Avoid grapefruit/grapefruit juice.
→Tell your clinician about all meds and supplements—CYP3A4 interactions can make levels spike or crash.

Side Effects

Most common psychiatric-relevant issues: akathisia (restlessness), extrapyramidal symptoms (parkinsonism), drowsiness or insomnia, agitation/anxiety, and nausea. Metabolic risk is usually lower than many antipsychotics, but not zero.

Common Things People Notice

Akathisia (inner restlessness, can’t sit still)
Parkinsonism (stiffness, tremor, slowed movement)
Drowsiness or feeling sedated (more common at higher doses, often improves)
Insomnia or sleep disruption
Agitation/anxiety or feeling keyed up (can overlap with akathisia)
Nausea/vomiting and stomach upset
Dizziness/orthostatic symptoms (lightheaded when standing)
Prolactin-related effects (sexual side effects, menstrual changes, breast symptoms)

Common Side Effects

Adults: ~6% to 22% reported; adolescents also reported

Akathisia— This can feel like anxiety, but it’s more physical—an internal motor that won’t shut off. It often appears early or after dose increases. If you’re pacing, can’t sit through a movie, or feel ‘crawly’ in your body, tell your prescriber quickly—this is treatable and sometimes a reason to slow titration or switch.

Adults: EPS reported up to ~5% to 39%; parkinsonism ~5% to 17%

Extrapyramidal symptoms (EPS) / Parkinsonism— Stiffness, tremor, slowed movement, jaw tightness, or swallowing changes can happen. These side effects are dose-related and may show up days to weeks after starting or increasing the dose.

Adults: ~7% to 26%

Drowsiness / Sedation— Latuda is often described as mildly to moderately sedating compared with other antipsychotics. Some people feel sleepy at night (helpful), others feel foggy. Sedation often improves over time, but if it’s flattening you, the dose or timing may need adjustment.

~5% to 11% reported

Insomnia / Sleep disturbance— Yes, both can happen: some people get sleepy, others get wired. If sleep gets worse, it may be dose-related, timing-related, or actually akathisia masquerading as ‘insomnia.’

Children/adolescents/adults: ~7% to 17%; vomiting also reported

Nausea / GI upset— Taking it with food helps tolerability and absorption. If nausea shows up early, it often settles, but persistent nausea matters—don’t just suffer through it silently.

Weight gain reported ~2% to 7%; lipid/glucose changes reported in labeling

Metabolic changes (weight, glucose, lipids)— Latuda is usually more metabolically friendly than many antipsychotics, and some people even improve labs when switching from higher-risk meds. Still: monitor weight, glucose/A1C, and lipids because risk isn’t zero.

Dose-dependent; elevated prolactin reported (higher thresholds noted in labeling tables)

Hyperprolactinemia— If you notice sexual side effects, menstrual changes, breast tenderness or discharge, acne/hirsutism changes, or fertility issues, bring it up. Sometimes the fix is dose, switching, or choosing a more prolactin-sparing option.

Serious side effects

Neuroleptic malignant syndrome (NMS): fever, severe rigidity, confusion, autonomic instability. MEDICAL EMERGENCY.
Tardive dyskinesia: involuntary movements (face/tongue/limbs), risk increases with long-term exposure and age; can be persistent.
Severe orthostatic hypotension/syncope and falls: injury risk, especially in older adults or dehydration.
Hematologic abnormalities: leukopenia, neutropenia, thrombocytopenia, anemia—monitor CBC if history of low counts or symptoms of infection.
Hyperglycemia/diabetes: uncommon compared with some SGAs but possible; monitor labs and symptoms (thirst, urination, fatigue).
Cardiac conduction issues/QT prolongation: overall QTc effect is minimal compared with many antipsychotics, but postmarketing QT prolongation has been reported—use caution with cardiac risk factors or interacting meds.
Temperature dysregulation/heat stroke risk: especially during heat exposure, dehydration, strenuous exercise.
Suicidal ideation reported postmarketing: monitor mood and safety, especially during early treatment or changes.

Critical Drug Interactions

Latuda is primarily metabolized by CYP3A4. Strong inhibitors can raise levels dangerously, and strong inducers can make it stop working. This is one of the most important interaction profiles to respect.

With: Strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)

Risk: Marked increase in lurasidone exposure → higher risk of EPS, sedation, hypotension, and other toxicity

Action: Contraindicated. Choose a different antipsychotic or a non-interacting anti-infective/antiviral strategy.

With: Strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort, avasimibe)

Risk: Marked decrease in lurasidone levels → loss of efficacy, relapse risk

Action: Contraindicated. Avoid combination; use an alternative agent.

With: Grapefruit / grapefruit juice

Risk: Can increase serum concentrations (CYP3A4 interaction) → more side effects

Action: Avoid grapefruit products while taking Latuda.

With: Other CNS-active meds that worsen movement side effects (certain antidepressants, stimulants, other antipsychotics)

Risk: Higher risk of akathisia/parkinsonism/EPS through additive dopamine blockade or activation effects

Action: Use caution with polypharmacy; monitor EPS closely during changes.

With: Blood pressure-lowering meds or dehydration states

Risk: Orthostatic hypotension and syncope risk increases

Action: Hydration, slow position changes, and close monitoring during initiation/titration.

Pregnancy, Breastfeeding, Special Groups

Pregnancy and postpartum are high-stakes contexts where the risk of untreated illness can be huge, and medication decisions should be shared and specialist-guided. For older adults, antipsychotics carry higher risks (falls, stroke, cognitive effects, and higher mortality in dementia-related psychosis). For kids and teens, metabolic and movement monitoring matters even if a medication is considered “lower risk.”

👶Pregnancy

Class-level data for second-generation antipsychotics do not show a clear major increase in congenital malformations overall, but lurasidone-specific data are limited. Third-trimester exposure to antipsychotics can lead to newborn EPS and/or withdrawal symptoms (agitation, abnormal tone, feeding issues, respiratory distress, somnolence, tremor). Avoiding relapse is often the priority—stopping an effective medication can raise relapse risk. Use the lowest effective dose and avoid polytherapy when possible; monitor symptom severity with a validated tool throughout pregnancy.

🤱Breastfeeding

Lurasidone is present in human milk. Limited data from one lactating patient suggest low infant exposure (relative infant dose reported <1%) and no observed adverse events in that case, but evidence is thin. If breastfeeding during treatment, monitor the infant for sedation, poor feeding, irritability, motor abnormalities, and slowed development—especially if the infant is premature/low birth weight or if other sedating medications are involved. Use the lowest effective dose and avoid multiple sedating meds when possible.

👧Children & Adolescents (Under 18)

Bipolar depression: approved down to age 10 (on its own). Schizophrenia: approved in adolescents. Children and teenagers may have higher EPS risk and need careful metabolic monitoring (weight/BMI, glucose/A1C, lipids) and movement monitoring. Long-term usefulness should be reviewed regularly as part of a total treatment plan (therapy, school supports, family work).

👴Older Adults (65+)

Avoid antipsychotics for behavioral problems associated with dementia or delirium unless non-medicine approaches fail and the person is at risk of harming themselves or others. Antipsychotics increase the risk of death in dementia-related psychosis. If used for appropriate conditions (eg, schizophrenia or bipolar disorder), use the lower range of adult dosing, titrate slowly, and monitor orthostasis, falls, movement symptoms, cognition and sodium.

🔬Liver Impairment

Moderate hepatic impairment (Child-Pugh B): start 20 mg daily; max 80 mg/day. Severe hepatic impairment (Child-Pugh C): start 20 mg daily; max 40 mg/day.

💧Kidney Impairment

CrCl <50 mL/min: start 20 mg daily; max 80 mg/day. CrCl ≥50 mL/min: no adjustment.

Clinical Monitoring

Adherence and dosing-with-food check at every visit: confirm ≥350 calories each dose and consistent timing
Mental status and target symptoms every visit: mood, psychosis intensity, agitation, sleep, functioning
Akathisia/EPS every visit (and ~4 weeks after initiation or dose change): ask directly about restlessness and do a brief movement exam; use a formal rating scale at least annually (more often if high risk)
Tardive dyskinesia screening every visit and formally at least annually (every 6 months if high risk): look for subtle face/tongue/hand movements early
Fall risk and orthostatic vitals every visit early on and after dose changes; counsel on slow position changes
Weight/BMI at baseline, around 8 and 12 weeks after start or dose change, then quarterly; consider waist circumference at baseline and annually
Fasting plasma glucose/A1C around 4 months after initiation, then annually (more often if abnormal or high risk)
Lipid panel around 4 months after initiation, then annually (more often if abnormal or high risk)
CBC as clinically indicated; monitor more closely if low baseline WBC/ANC or history of drug-induced leukopenia/neutropenia
Electrolytes/renal/liver function annually (or sooner if clinically indicated); monitor sodium closely in older adults due to SIADH/hyponatremia risk class-wide
Prolactin: ask about symptoms at every visit until dose is stable; check level if symptoms (sexual dysfunction, menstrual changes, galactorrhea, gynecomastia)
Temperature regulation counseling during heat exposure and strenuous exercise: hydration and warning signs of heat illness

How Well It Works

Clinical improvement timeline

Early changes often within 1–2 weeks

Latuda can be effective for bipolar depression and schizophrenia, but it typically works in layers: early shifts in the first 1–2 weeks, followed by steadier improvement over 4–6 weeks. Consistency matters—and with this medication, the food requirement is part of consistency.

Mechanism of Action

Latuda works by balancing dopamine and serotonin signaling in the brain—mainly by blocking dopamine D2 receptors and serotonin 5-HT2A receptors, with additional activity at 5-HT7 and partial agonism at 5-HT1A. The dopamine piece targets psychosis and agitation; the serotonin profile may help mood and cognition. It has little to no meaningful activity at histamine H1 or muscarinic M1 receptors, which is one reason it’s often less sedating and less anticholinergic than some alternatives—though side effects can still happen.

Place in Treatment Algorithm

Latuda is a common choice when treating schizophrenia or bipolar depression, especially if weight gain, diabetes risk, or lipid issues are a major concern with other antipsychotics. It’s not a medication for acute mania/hypomania. The biggest practical rule is absorption: you need a real meal (≥350 calories). If you don’t build that into your routine, you can end up with inconsistent benefit and confusing side effects. Titration should be guided by tolerability—akathisia and parkinsonism are the side effects that most often determine whether Latuda is the right fit.

Questions people ask

What is Latuda used for?

Latuda (lurasidone) is used to treat schizophrenia and depressive episodes in bipolar I disorder (bipolar depression). It’s not a treatment for acute bipolar mania or hypomania.

How fast does Latuda work?

Some people notice early changes within about 1–2 weeks (sometimes sooner for bipolar depression), but the more consistent benefit usually builds over 4–6 weeks. If you’re not taking it with enough food, it can look like it “isn’t working” even when the dose is right on paper.

Do I really have to take Latuda with food?

Yes. Latuda needs at least 350 calories to absorb properly. Without food, your body gets way less of the medication—so you can end up with inconsistent results and a very confusing trial.

What’s the most common reason people stop Latuda?

A strong inner restlessness (akathisia) is a big one. It can feel like anxiety but it’s more physical—pacing, can’t sit still, “crawling” energy. The good news: it’s often manageable if caught early, and sometimes it means raising the dose more slowly or choosing a different medication.

Does Latuda cause weight gain?

Compared with many antipsychotics, Latuda is usually associated with minimal to low weight and metabolic risk. But “lower risk” doesn’t mean “no risk.” Some people still gain weight or have changes in glucose or lipids, so monitoring matters.

What medications can’t be taken with Latuda?

Medicines that strongly slow or strongly speed up how lurasidone is broken down are the main problem, and generally should not be used with it (they can make levels dangerously high or make the medicine stop working). Grapefruit can also raise levels—avoid it.

Is Latuda approved for dementia-related psychosis?

No. Antipsychotics raise the risk of death in older adults with dementia-related psychosis, and Latuda is not approved for that use.

How do I stop Latuda safely?

Don’t stop suddenly unless there’s a serious side effect that requires stopping right away. If stopping is the plan, lower the dose gradually over weeks to months so you can catch early relapse symptoms and reduce withdrawal reactions like agitation, anxiety, trouble sleeping, sweating, shaking, stomach upset, and return of psychosis or mood symptoms.

Can Latuda be used postpartum?

Latuda has been used off-label in postpartum psychosis in some specialist-guided protocols. Postpartum decisions are high-stakes—treatment should be individualized, and risks of untreated illness are real. If breastfeeding, infant monitoring for sedation/feeding issues is important because lurasidone can be present in milk.

What should be monitored while taking Latuda?

At visits: symptoms, side effects, movement symptoms (restlessness, stiffness, involuntary movements), blood pressure when standing and fall risk, and whether you’re taking it as prescribed—including with food. Over time: weight/BMI, blood sugar/A1C, cholesterol and prolactin symptoms. Blood counts and other blood tests are checked when needed, especially if there’s a history of low white blood cells or other risk factors.

What It's Used For

Primary Indications

Off-Label Uses

Bipolar depressive episodes with mixed featuresMajor depressive disorder with mixed featuresPostpartum psychosis (specialist-directed)

How Fast It Works

Latuda isn’t an instant tranquilizer. It’s more of a steady-build medication—early changes first, then deeper improvement over weeks.

Within 1 week (often)

early improvement in bipolar depression can start showing up

1–2 weeks

early schizophrenia symptom shifts may begin (less intensity, less agitation)

4–6 weeks

fuller effect is more likely to be noticeable and consistent

Once daily dosing

long half-life supports daily dosing rather than multiple times per day

Food is part of the dose

taking it with ≥350 calories meaningfully changes how much medication your body absorbs

Safe Discontinuation

Key Points

Don’t stop abruptly unless there’s a serious adverse effect requiring urgent discontinuation.
Taper over several weeks to months when possible to reduce withdrawal symptoms and detect symptom recurrence early.
Withdrawal symptoms can include agitation, anxiety, insomnia, sweating, GI symptoms, chills/warmth waves, tremor, restlessness, dizziness/vertigo, dyskinesias, and return of psychosis or mood symptoms.
If switching antipsychotics: common strategies include cross-titration, overlap-and-taper, or (less commonly) abrupt change with careful monitoring; relapse risk level should drive how conservative you are.
If schizophrenia relapse risk is high, clinicians may overlap (keep the current med stable while the new med reaches a therapeutic dose) before tapering the first medication.

Dosing Information

Adult Dosing

schizophrenia initial: 40 mg PO once daily in the evening within 30 minutes of food (≥350 calories); consider 20 mg once daily for first-episode psychosis or sensitivity to side effects

schizophrenia titration: Increase in 40 mg increments no sooner than every 3 days based on response and tolerability; monitor akathisia, parkinsonism, and sedation during titration

schizophrenia typical: 40 to 80 mg/day; use the lowest effective maintenance dose

schizophrenia max: 160 mg/day

bipolar depression initial: 20 mg PO once daily in the evening within 30 minutes of food (≥350 calories)

bipolar depression titration: Increase by 20 mg increments every ≥2 days based on response and tolerability

bipolar depression max: 120 mg/day

mdd mixed features initial: 20 mg PO once daily in the evening within 30 minutes of food (≥350 calories) for 7 days

mdd mixed features titration: After day 7, increase by 20 mg every 2 to 7 days based on response and tolerability

mdd mixed features max: 60 mg/day

postpartum psychosis initial: 40 mg PO once daily in the evening within 30 minutes of food (≥350 calories)

postpartum psychosis titration: After 3 days increase to 80 mg once daily; after 2 to 3 additional days may increase further up to 160 mg/day over ~1 week based on response and tolerability

postpartum psychosis duration: Continue treatment for 3 to 6 months (specialist-guided)

renal impairment: CrCl <50 mL/min: Start 20 mg PO daily; maximum 80 mg/day (CrCl ≥50 mL/min: no adjustment)

hepatic impairment: Child-Pugh B: Start 20 mg PO daily; maximum 80 mg/day. Child-Pugh C: Start 20 mg PO daily; maximum 40 mg/day (Child-Pugh A: no adjustment)

Simple Explanation

Available Formulations

Tablets: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg (brand and generic availability varies by country)
Administration: Once daily with food (≥350 calories), ideally at the same time each day

Critical Safety Information

Not approved for dementia-related psychosis. Antipsychotics raise the risk of death in older adults with dementia-related psychosis.

→Take Latuda with at least 350 calories every time. If you skip the food, you may be under-dosing without realizing it.
→Call urgently for high fever + muscle stiffness + confusion (possible NMS).
→Report restlessness you can’t control (akathisia), new tremor/stiffness, or swallowing problems—these can be movement side effects that need fast fixes.
→Stand up slowly and hydrate, especially early on—dizziness and fainting can happen.
→If you’re older or medically fragile, fall risk is real. Build in safety (night lights, slow position changes).
→Avoid grapefruit/grapefruit juice.
→Tell your clinician about all meds and supplements—CYP3A4 interactions can make levels spike or crash.

Side Effects

Common Things People Notice

Akathisia (inner restlessness, can’t sit still)
Parkinsonism (stiffness, tremor, slowed movement)
Drowsiness or feeling sedated (more common at higher doses, often improves)
Insomnia or sleep disruption
Agitation/anxiety or feeling keyed up (can overlap with akathisia)
Nausea/vomiting and stomach upset
Dizziness/orthostatic symptoms (lightheaded when standing)
Prolactin-related effects (sexual side effects, menstrual changes, breast symptoms)

Common Side Effects

Adults: ~6% to 22% reported; adolescents also reported

Adults: EPS reported up to ~5% to 39%; parkinsonism ~5% to 17%

Adults: ~7% to 26%

~5% to 11% reported

Children/adolescents/adults: ~7% to 17%; vomiting also reported

Nausea / GI upset— Taking it with food helps tolerability and absorption. If nausea shows up early, it often settles, but persistent nausea matters—don’t just suffer through it silently.

Weight gain reported ~2% to 7%; lipid/glucose changes reported in labeling

Dose-dependent; elevated prolactin reported (higher thresholds noted in labeling tables)

Serious side effects

Neuroleptic malignant syndrome (NMS): fever, severe rigidity, confusion, autonomic instability. MEDICAL EMERGENCY.
Tardive dyskinesia: involuntary movements (face/tongue/limbs), risk increases with long-term exposure and age; can be persistent.
Severe orthostatic hypotension/syncope and falls: injury risk, especially in older adults or dehydration.
Hematologic abnormalities: leukopenia, neutropenia, thrombocytopenia, anemia—monitor CBC if history of low counts or symptoms of infection.
Hyperglycemia/diabetes: uncommon compared with some SGAs but possible; monitor labs and symptoms (thirst, urination, fatigue).
Cardiac conduction issues/QT prolongation: overall QTc effect is minimal compared with many antipsychotics, but postmarketing QT prolongation has been reported—use caution with cardiac risk factors or interacting meds.
Temperature dysregulation/heat stroke risk: especially during heat exposure, dehydration, strenuous exercise.
Suicidal ideation reported postmarketing: monitor mood and safety, especially during early treatment or changes.

Critical Drug Interactions

With: Strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)

Risk: Marked increase in lurasidone exposure → higher risk of EPS, sedation, hypotension, and other toxicity

Action: Contraindicated. Choose a different antipsychotic or a non-interacting anti-infective/antiviral strategy.

With: Strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort, avasimibe)

Risk: Marked decrease in lurasidone levels → loss of efficacy, relapse risk

Action: Contraindicated. Avoid combination; use an alternative agent.

With: Grapefruit / grapefruit juice

Risk: Can increase serum concentrations (CYP3A4 interaction) → more side effects

Action: Avoid grapefruit products while taking Latuda.

With: Other CNS-active meds that worsen movement side effects (certain antidepressants, stimulants, other antipsychotics)

Risk: Higher risk of akathisia/parkinsonism/EPS through additive dopamine blockade or activation effects

Action: Use caution with polypharmacy; monitor EPS closely during changes.

With: Blood pressure-lowering meds or dehydration states

Risk: Orthostatic hypotension and syncope risk increases

Action: Hydration, slow position changes, and close monitoring during initiation/titration.

Pregnancy, Breastfeeding, Special Groups

👶Pregnancy

🤱Breastfeeding

👧Children & Adolescents (Under 18)

👴Older Adults (65+)

🔬Liver Impairment

Moderate hepatic impairment (Child-Pugh B): start 20 mg daily; max 80 mg/day. Severe hepatic impairment (Child-Pugh C): start 20 mg daily; max 40 mg/day.

💧Kidney Impairment

CrCl <50 mL/min: start 20 mg daily; max 80 mg/day. CrCl ≥50 mL/min: no adjustment.

Clinical Monitoring

Adherence and dosing-with-food check at every visit: confirm ≥350 calories each dose and consistent timing
Mental status and target symptoms every visit: mood, psychosis intensity, agitation, sleep, functioning
Akathisia/EPS every visit (and ~4 weeks after initiation or dose change): ask directly about restlessness and do a brief movement exam; use a formal rating scale at least annually (more often if high risk)
Tardive dyskinesia screening every visit and formally at least annually (every 6 months if high risk): look for subtle face/tongue/hand movements early
Fall risk and orthostatic vitals every visit early on and after dose changes; counsel on slow position changes
Weight/BMI at baseline, around 8 and 12 weeks after start or dose change, then quarterly; consider waist circumference at baseline and annually
Fasting plasma glucose/A1C around 4 months after initiation, then annually (more often if abnormal or high risk)
Lipid panel around 4 months after initiation, then annually (more often if abnormal or high risk)
CBC as clinically indicated; monitor more closely if low baseline WBC/ANC or history of drug-induced leukopenia/neutropenia
Electrolytes/renal/liver function annually (or sooner if clinically indicated); monitor sodium closely in older adults due to SIADH/hyponatremia risk class-wide
Prolactin: ask about symptoms at every visit until dose is stable; check level if symptoms (sexual dysfunction, menstrual changes, galactorrhea, gynecomastia)
Temperature regulation counseling during heat exposure and strenuous exercise: hydration and warning signs of heat illness

How Well It Works

Clinical improvement timeline

Early changes often within 1–2 weeks

Mechanism of Action

Place in Treatment Algorithm

Questions people ask

What is Latuda used for?

Latuda (lurasidone) is used to treat schizophrenia and depressive episodes in bipolar I disorder (bipolar depression). It’s not a treatment for acute bipolar mania or hypomania.

How fast does Latuda work?

Do I really have to take Latuda with food?

Yes. Latuda needs at least 350 calories to absorb properly. Without food, your body gets way less of the medication—so you can end up with inconsistent results and a very confusing trial.

What’s the most common reason people stop Latuda?

Does Latuda cause weight gain?

What medications can’t be taken with Latuda?

Is Latuda approved for dementia-related psychosis?

No. Antipsychotics raise the risk of death in older adults with dementia-related psychosis, and Latuda is not approved for that use.

What it feels like

Mood lift (bipolar depression)

What it's for

Lurasidone for Schizophrenia

Side effects

Drowsiness / Sedation

Your situation

Get help right away if

The full guide

What it's for

Taking it

Safety

How it works

Questions

What it feels like

Mood lift (bipolar depression)

What it's for

Lurasidone for Schizophrenia

Side effects

Drowsiness / Sedation

Your situation

Get help right away if

The full guide

What it's for

Taking it

Safety

How it works

Questions